000154617 001__ 154617
000154617 005__ 20240229123107.0
000154617 0247_ $$2doi$$a10.1158/1055-9965.EPI-19-1545
000154617 0247_ $$2pmid$$apmid:32332031
000154617 0247_ $$2ISSN$$a1055-9965
000154617 0247_ $$2ISSN$$a1538-7755
000154617 0247_ $$2altmetric$$aaltmetric:80675502
000154617 037__ $$aDKFZ-2020-00890
000154617 041__ $$aeng
000154617 082__ $$a610
000154617 1001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia Anna$$b0$$eFirst author
000154617 245__ $$aAntibody responses to Helicobacter pylori and risk of developing colorectal cancer in a European cohort.
000154617 260__ $$aPhiladelphia, Pa.$$bAACR$$c2020
000154617 3367_ $$2DRIVER$$aarticle
000154617 3367_ $$2DataCite$$aOutput Types/Journal article
000154617 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1635317138_24039
000154617 3367_ $$2BibTeX$$aARTICLE
000154617 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154617 3367_ $$00$$2EndNote$$aJournal Article
000154617 500__ $$a2020 Jul;29(7):1475-1481.#EA:F022#LA:F022#
000154617 520__ $$aWhile Helicobacter pylori (H. pylori) is the major cause of gastric cancer, it has also been suggested to be involved in colorectal cancer (CRC) development. However, prospective studies addressing H. pylori and CRC are sparse and inconclusive. We assessed the association of antibody responses to H. pylori proteins with CRC in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.We applied H. pylori multiplex serology to measure antibody responses to 13 H. pylori proteins in pre-diagnostic serum samples from 485 CRC cases and 485 matched controls nested within the EPIC study. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using multivariable conditional logistic regression to estimate the association of H. pylori overall and protein-specific sero-positivity with odds of developing CRC.Fifty-one percent of CRC cases were H. pylori sero-positive compared to 44% of controls resulting in an OR of 1.36 (95% CI: 1.00-1.85). Among the 13 individual H. pylori proteins, the association was driven mostly by sero-positivity to Helicobacter cysteine-rich protein C (HcpC) (OR: 1.66, 95% CI: 1.19-2.30) and Vacuolating cytotoxin A (VacA) (OR: 1.34, 95% CI: 0.99-1.82), the latter being non-statistically significant only in the fully adjusted model.In this prospective multi-center European study, antibody responses to H. pylori proteins, specifically HcpC and VacA, were associated with an increased risk of developing CRC.Biological mechanisms for a potential causal role of H. pylori in colorectal carcinogenesis need to be elucidated, and subsequently whether H. pylori eradication may decrease CRC incidence.
000154617 536__ $$0G:(DE-HGF)POF3-316$$a316 - Infections and cancer (POF3-316)$$cPOF3-316$$fPOF III$$x0
000154617 588__ $$aDataset connected to CrossRef, PubMed,
000154617 7001_ $$aJenab, Mazda$$b1
000154617 7001_ $$0P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aPawlita, Michael$$b2
000154617 7001_ $$00000-0003-4385-2097$$aTjonneland, Anne$$b3
000154617 7001_ $$00000-0002-9083-8960$$aKyrø, Cecilie$$b4
000154617 7001_ $$00000-0002-5956-5693$$aBoutron-Ruault, Marie-Christine$$b5
000154617 7001_ $$aCarbonnel, Franck$$b6
000154617 7001_ $$aDong, Catherine$$b7
000154617 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b8
000154617 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b9
000154617 7001_ $$aBoeing, Heiner$$b10
000154617 7001_ $$00000-0002-0830-5277$$aSchulze, Matthias B$$b11
000154617 7001_ $$aTrichopoulou, Antonia$$b12
000154617 7001_ $$00000-0002-3275-2026$$aKarakatsani, Anna$$b13
000154617 7001_ $$00000-0003-1441-897X$$aLa Vecchia, Carlo$$b14
000154617 7001_ $$00000-0002-5558-2437$$aPalli, Domenico$$b15
000154617 7001_ $$aAgnoli, Claudia$$b16
000154617 7001_ $$00000-0003-2666-414X$$aTumino, Rosario$$b17
000154617 7001_ $$aSacerdote, Carlotta$$b18
000154617 7001_ $$aPanico, Salvatore$$b19
000154617 7001_ $$aBueno-de-Mesquita, Bas$$b20
000154617 7001_ $$aVermeulen, Roel$$b21
000154617 7001_ $$00000-0002-0031-4152$$aGram, Inger T$$b22
000154617 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b23
000154617 7001_ $$00000-0002-1741-2322$$aBenjaminsen Borch, Kristin$$b24
000154617 7001_ $$aQuirós, J Ramón$$b25
000154617 7001_ $$aAgudo, Antonio$$b26
000154617 7001_ $$00000-0002-9972-9779$$aRodríguez-Barranco, Miguel$$b27
000154617 7001_ $$aSantiuste, Carmen$$b28
000154617 7001_ $$00000-0001-8434-2013$$aArdanaz, Eva$$b29
000154617 7001_ $$00000-0002-9692-101X$$aVan Guelpen, Bethany$$b30
000154617 7001_ $$00000-0001-8540-6891$$aHarlid, Sophia$$b31
000154617 7001_ $$00000-0002-3777-4953$$aImaz, Liher$$b32
000154617 7001_ $$00000-0002-5652-356X$$aPerez-Cornago, Aurora$$b33
000154617 7001_ $$aGunter, Marc J$$b34
000154617 7001_ $$aZouiouich, Semi$$b35
000154617 7001_ $$00000-0003-2491-5099$$aPark, Jin Young$$b36
000154617 7001_ $$aRiboli, Elio$$b37
000154617 7001_ $$00000-0002-0893-2377$$aCross, Amanda J$$b38
000154617 7001_ $$00000-0001-6517-1300$$aHeath, Alicia K$$b39
000154617 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b40$$eLast author
000154617 7001_ $$00000-0003-1668-8770$$aHughes, David J$$b41
000154617 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-19-1545$$gp. cebp.1545.2019 -$$n7$$p1475-1481$$tCancer epidemiology, biomarkers & prevention$$v29$$x1538-7755$$y2020
000154617 909CO $$ooai:inrepo02.dkfz.de:154617$$pVDB
000154617 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000154617 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000154617 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000154617 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000154617 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b40$$kDKFZ
000154617 9131_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000154617 9141_ $$y2020
000154617 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2017
000154617 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000154617 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000154617 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000154617 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000154617 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000154617 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000154617 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000154617 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000154617 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000154617 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000154617 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000154617 9201_ $$0I:(DE-He78)F022-20160331$$kF022$$lInfektionen und Krebs-Epidemiologie$$x0
000154617 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x1
000154617 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000154617 9200_ $$0I:(DE-He78)F022-20160331$$kF022$$lF022 Infektionen und Krebs-Epidemiologie$$x0
000154617 980__ $$ajournal
000154617 980__ $$aVDB
000154617 980__ $$aI:(DE-He78)F022-20160331
000154617 980__ $$aI:(DE-He78)F020-20160331
000154617 980__ $$aI:(DE-He78)C020-20160331
000154617 980__ $$aUNRESTRICTED